In July 2016, Synthorx raised $10 Million to develop and scale novel protein therapeutics with improved pharmacological properties. The Series B financing was led by RA Capital Management and joined by Series A investors Avalon Ventures and Correlation Ventures. (read the press release here).
John Carroll’s new biotech blog, Endpoints News, explored Synthorx’s big (and some small, near-term) R&D goals for creating improved protein therapeutics.
The groundbreaking potential of Synthorx’s technology is the ability to insert synthetic DNA in bacteria and efficiently produce proteins with multiple synthetic amino acids at low cost and at sufficient scale for drug discovery and development. “We are the only company where you can add synthetic amino acids to any size protein or peptide and produce it at scale,” Turner said.